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Abstract 
The British Association for Psychopharmacology (BAP) coordinated a meeting of experts 
to review and revise its previous (2011) Guidelines for clinical practice with anti-dementia 
drugs. As before, levels of evidence were rated using accepted standards which were then 
translated into grades of recommendation A to D, with A having the strongest evidence 
base (from randomised controlled trials) and D the weakest (case studies or expert opinion).  
Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in 
clinical practice (B) and both structural (CT and MRI) and functional (PET and SPECT) 
brain imaging can improve diagnostic accuracy in particular situations (B). Cholinesterase 
inhibitors (ChEI; donepezil, rivastigmine, and galantamine) are effective for cognition in 
mild to moderate Alzheimer’s disease (AD)(A), memantine for moderate to severe AD  (A) 
and combination therapy (ChEI and memantine) may be beneficial (B). Drugs should not 
be stopped just because dementia severity increases (A). Until further evidence is available 
other drugs, including statins, anti-inflammatory drugs, vitamin E, nutritional supplements 
and ginkgo biloba, cannot be recommended either for the treatment or prevention of AD 
(A). Neither ChEI nor memantine are effective in those with Mild Cognitive Impairment 
(A). ChEI are not effective in frontotemporal dementia and may cause agitation (A), though 
selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features 
(B). ChEI should be used for the treatment of people with Lewy body dementias (both 
Parkinson's disease dementia and dementia with Lewy bodies), and memantine may be 
helpful (A). No drugs are clearly effective in vascular dementia, though ChEI are beneficial 
in mixed dementia (B). Early evidence suggests multifactorial interventions may have 
potential to prevent or delay the onset of dementia (B). Though the consensus statement 
focuses on medication, psychological interventions can be effective in addition to 
pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel 
pharmacological approaches involving strategies to reduce amyloid and/or tau deposition in 
those with or at high risk of AD are in progress. Though results of pivotal studies in early 
(prodromal/mild) AD are awaited, results to date in more established (mild to moderate) 
AD have been equivocal and no disease modifying agents are either licensed or can be 
currently recommended for clinical use.   
Keywords 
Dementia, Alzheimer’s disease, Lewy, vascular, frontotemporal, guidelines, treatment, 
management 
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Introduction 
The British Association for Psychopharmacology (BAP) produced a first edition of clinical 
practice guidelines for anti-dementia drugs in 2006 (Burns and O'Brien, 2006), which were 
subsequently revised (O'Brien and Burns, 2011). As with other BAP guidelines, these were 
explicitly based on the published evidence available and formulated by an expert group 
following a face to face consensus meeting. Given advances in the field, a review of these 
guidelines was planned at that stage for five years later. An expert consensus group 
therefore reconvened to review and grade the strength of current evidence, consider its 
clinical implications and agree on revised guidelines for the use of anti-dementia drugs. The 
focus was on new evidence which had become available since the first guidelines were 
published. The current, third, revision of the guidelines have been drawn up after extensive 
feedback from participants and have undergone independent peer review prior to 
publication. The revised guideline covers the diagnosis of dementia, its treatment with anti-
dementia drugs, its management in primary and secondary care and its prevention. The 
guidelines do not directly deal with drug treatments specifically for behavioural 
disturbances in dementia (e.g. antidepressants, antipsychotics and other agents) but do 
consider these symptoms when impacted upon by drugs aimed specifically at the disease 
processes thought to underpin the cognitive decline.  
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Dementia affects around 800 000 people in the UK, of which Alzheimer’s disease 
(AD) is the commonest cause (60%) followed by vascular dementia (VaD, 15-20%), 
dementia with Lewy bodies (DLB, 10-15%), frontotemporal dementias, other rarer causes 
and occasionally reversible conditions (5%). These figures include a substantial proportion 
of cases where there is evidence of mixed pathology, which is more common in older 
people. The diagnosis of subtype of dementia is based on clinical history, physical and 
mental state (cognitive) examination and appropriate investigations. Currently the mainstay 
of pharmacological treatment for the cognitive deficits of AD are the cholinesterase 
inhibitors (ChEI; donepezil, Aricept®; galantamine, Reminyl®; and rivastigmine, 
Exelon®), which are licensed for the treatment of mild to moderate disease; and 
memantine, (Ebixa®) licensed for moderate to severe illness. There is general agreement 
that anticholinergic burden should be minimised in those with dementia, especially before 
prescribing cholinergic medication. Anticholinergic use has been associated with poorer 
cognitive and functional performance, cognitive decline (Ancelin et al. 2006; Fox et al. 
2011; Shah et al. 2013) and with increased risk for dementia (Gray et al. 2015). Scales to 
assess anticholinergic burden are available (for reviews see Salahudeen et al. 2015; 
Cardwell et al. 2015) and while minimising anticholinergic burden makes clinical sense, 
there are no definitive studies on the effects of such a reduction on cognitive and functional 
decline in people with dementia.  
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Associated non-cognitive symptoms, often called behavioural and psychological 
symptoms of dementia (BPSD), are frequently seen in all dementias, cause distress to 
patients and carers and are a major factor in predicting institutional care. Many types of 
BPSD, including agitation, aggression and psychosis, have traditionally been treated with 
neuroleptic (antipsychotic) agents. However,  concerns over cerebrovascular adverse events 
and increased mortality has forced consideration of alternative approaches to the treatment 
of BPSD, including ChEI, memantine and increased the emphasis on non-pharmacological 
therapies including activity, music therapy and  aromatherapy. Management of VaD 
primarily involves the identification and treatment of vascular risk factors, amelioration of 
BPSD and, where there is coexistent AD, prescription of ChEI and memantine. DLB is 
treated symptomatically with cautious use of anti-parkinsonian medication where necessary 
(L-dopa monotherapy having the least propensity to exacerbate psychosis) and ChEI. 
Management of BPSD is more challenging and antipsychotic drugs should be avoided 
because of parkinsonian side effects and the likelihood of prolonged and severe sensitivity 
reactions. 
Other guidelines and guidance are available for the diagnosis and treatment of 
dementia, including those of the National Institute for Health and Clinical Excellence 
(www.nice.org.uk), the European Federation of Neurological Sciences (Hort et al., 2010; 
Schmidt et al., 2015; Waldemar et al., 2007), the American Academy of Neurology 
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(Knopman et al., 2001) and the Scottish Intercollegiate Guidelines network (SIGN) 
(www.sign.ac.uk). Guidelines are also available on non-pharmacological management, 
which is not discussed in detail here (BPS, 2014).  
Methodology 
We held a consensus meeting in London in March 2016. The participants were selected for 
their clinical and research experience in the field of dementia care, and also included a 
person with dementia. The group arrived at its decisions after expert papers were written 
independently and then presented and discussed at the meeting. Guidelines were then 
prepared following the format of previous BAP consensus meetings, and the first and 
second consensus meetings on anti-dementia drugs (Burns and O’Brien, 2006; Burns and 
O’Brien, 2011). All participants provided an evidence summary based on their own expert 
knowledge of the literature, combined with a recent literature review in their own specialist 
area. All relevant papers published up to and including December 2015 were considered. 
Particular emphasis was placed on reviewing the previous recommendations in the light of 
new evidence published since the last guidelines. The objectives of the guideline were to: 
1. Review evidence for the clinical diagnosis of dementia and its subtypes and the role 
of investigations in improving diagnostic accuracy. 
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2. Assess the evidence for the efficacy of currently available anti-dementia drugs in all 
common types of dementia and, based on that, make clear recommendations for 
clinical practice. 
3. Appraise the evidence for the efficacy of drugs for those with pre-dementia 
conditions such as Mild Cognitive Impairment or prodromal/ preclinical dementia 
4. Appraise the evidence for drugs with potential to delay or prevent dementia, or 
modify its disease course. 
The level of evidence was categorised according to standard criteria, and level of evidence 
was then translated into strength of recommendation as detailed in Table 1.  
 
Table 1. Categories of evidence and strength of recommendation1 
Categories of evidence for causal relationships and treatment 
I Evidence from meta-analysis of randomised controlled trials*, at least one large, 
good quality, randomised controlled trial* or replicated, smaller, randomised 
controlled trials* 
II Evidence from small, non-replicated, randomised controlled trials*, at least one 
controlled study without randomisation or evidence from at least one other type of 
quasi-experimental study 
III Evidence from non-experimental descriptive studies, such as uncontrolled, 
comparative, correlation and case-control studies 
IV Evidence from expert committee reports or opinions and/or clinical experience of 
respected authorities 
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Proposed categories of evidence for non-causal relationships 
I Evidence from large representative population samples 
II Evidence from small, well designed, but not necessarily representative samples 
III Evidence from non-representative surveys, case reports 
IV Evidence from expert committee reports or opinions and/or clinical experience of 
respected authorities 
Strength of recommendation 
A Directly based on category I evidence 
B Directly based on category II evidence or extrapolated# recommendation from 
category I evidence 
C Directly based on category III evidence or extrapolated# recommendation from 
category I or II evidence 
D Directly based on category IV evidence or extrapolated# recommendation from 
category I, II or III evidence 
1 (Anderson et al., 2008) 
* Randomised controlled trials must have an appropriate control treatment arm; for primary 
efficacy this should include a placebo condition. 
 
# Extrapolation may be necessary because of evidence that is only indirectly related, covers 
only a part or the area of practice under consideration, has methodological problems or is 
contradictory. 
 
Diagnosis and investigations  
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The criteria used to define dementia and cognitive disorders continue to cause controversy. 
Since the last guideline, a revision of the influential Diagnostic and Statistical Manual 
(DSM 5) has been published (American Psychiatric Association, 2013). Two key changes 
from DSM-IV TR (American Psychiatric Association, 2000) of relevance here are a) a 
move away from the terms of dementia and mild cognitive impairment to major and mild 
neurocognitive disorder respectively and b) the inclusion of Lewy body disorder (major or 
mild neurocognitive disorder with Lewy bodies). There have been several proposals to 
revise the criteria for AD, with the inclusion of biomarkers aiming to both improve the 
accuracy of diagnosis, and allow diagnosis at an earlier pre-dementia or prodromal stage. 
The International Working Group has proposed criteria for very early AD (Dubois et al., 
2007), which were later expanded to include prodromal AD (Dubois et al., 2010) and 
further revised to include amyloid imaging (Dubois et al., 2014). The NIA-AA group has 
published new criteria for AD dementia (McKhann et al., 2011), mild cognitive impairment 
due to AD (Albert et al., 2011) and preclinical AD (Sperling et al., 2011). Within these 
criteria, prodromal AD or mild cognitive impairment due to AD refers to early (pre-
dementia) but symptomatic disease, whilst preclinical refers to pre-symptomatic or “at risk” 
states. The main purpose of many of these changes has been to allow internationally agreed 
criteria to be used for subject selection and stratification for ongoing natural history and 
therapeutic studies, though the validation and clinical usefulness of these criteria remains to 
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be fully determined. There have been no new revisions of the criteria for DLB  (McKeith et 
al., 2005) or Parkinson's disease dementia (Emre et al., 2007) since the last guideline, 
though the DLB criteria are under review at the time of writing. In keeping with the moves 
in the Alzheimer field towards earlier diagnosis, criteria for mild cognitive impairment in 
Parkinson’s disease have been published (Litvan et al., 2012).   
Clinical criteria for Frontotemporal Dementia (FTD) have been updated (Rascovsky 
et al., 2011). New criteria are sensitive and specific for the diagnosis of behavioural variant 
FTD although the related syndromes of semantic dementia and progressive non-fluent 
aphasia are now classified according to new primary progressive aphasia (PPA) 
recommendations (Gorno-Tempini et al., 2011)(see Figure 1). The PPA classification 
system has lower diagnostic accuracy in terms of predicting pathological diagnosis and 
includes a clinical syndrome mostly associated with Alzheimer pathology (Mesulam and 
Weintraub, 2014). This poses further potential problems in performing and interpreting 
treatment trials in this disease area. There have been no internationally agreed formal 
revisions of criteria for VaD, but consensus groups have offered frameworks whereby some 
apparently contradictory concepts, such as the dimensional nature of vascular cognitive 
impairment (O’Brien et al., 2003) can to some extent be reconciled with the dimensional 
approach of major and minor neurocognitive disorder (Sachdev et al., 2014). What is clear 
is that in all areas, new knowledge, especially regarding genetics and biomarkers, and the 
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need to stratify people at an early stage in their disease, have been the driving forces behind 
these revisions, more of which can be expected over time as further advances are made.   
 
Neuroimaging and CSF biomarkers 
There is increasing interest in the use of brain imaging and cerebrospinal fluid (CSF) 
biomarkers, both to assist with early and accurate differential diagnosis, and as potential 
markers of disease progression which may be used as surrogate outcome measures for 
clinical trials.  
Brain imaging is extensively used to assist with diagnosis, both by excluding other 
causes for a dementia syndrome and providing information to support a subtype specific 
diagnosis (for review see O’Brien, 2007). Evidence for its use in excluding other causes for 
cognitive impairment and for supporting subtype diagnosis of dementia was discussed in 
the first and second guideline. Cerebrovascular changes on imaging are necessary for the 
application of standard diagnostic criteria for VaD (Román et al., 1993), and increasingly 
imaging changes are being incorporated into other diagnostic criteria. FTD is associated 
with frontal and anterior temporal lobe atrophy, with a variable extent of hippocampal 
atrophy depending on the subtype, on structural imaging and frontotemporal hypoperfusion 
on Single Photon Emission Computerised Tomography (SPECT) and hypometabolism on 
FDG PET (Fluoro-deoxy glucose Positron Emission Tomography). AD is associated with 
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medial temporal lobe atrophy, particularly of the entorhinal cortex and hippocampus, and 
temporoparietal hypoperfusion on SPECT and hypometabolism on FDG PET. Early onset 
AD is also associated with parietal and precuneus atrophy. Preservation of the medial 
temporal lobe in DLB has emerged as the most robust structural imaging marker separating 
DLB from AD and has been confirmed in studies with autopsy verification (Burton et al., 
2009). DLB is associated with  hypoperfusion and hypometabolism of posterior parietal 
and occipital areas on SPECT and FDG PET respectively (Colloby et al., 2008).  A blinded 
study comparing FDG-PET with hexamethylpropylene amine oxime (HMPAO) SPECT in 
the diagnosis of degenerative (AD or  DLB) dementia from controls found a clear (20%) 
superiority for FDG-PET over HMPAO SPECT in diagnostic accuracy (O’Brien et al., 
2014). Dopaminergic SPECT or PET can distinguish DLB from AD with 80% sensitivity 
and 90% specificity (McKeith et al., 2007; O’Brien et al., 2014). Decreased cardiac 
sympathetic uptake, as indicated by decreased metaiodobenzylguanidine (MIBG) SPECT 
binding has been found in Parkinson's disease and DLB. MIBG imaging has now been 
shown in single and now multi-centre studies to distinguish DLB from AD with 70% 
sensitivity and 90% specificity (Yoshita et al., 2015). 
Amyloid PET imaging can be undertaken with C11-PIB and, since the last guideline, 
three fluorinated compounds which have all received a licence for demonstrating increased 
brain amyloid as an adjunct to diagnosing AD (florbetapir, flurbetaben and flutemetamol). 
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These have all been subject to autopsy validation studies, where a positive amyloid scan 
predicts significant plaque pathology at autopsy with >90% certainty, and clinical studies 
indicating good diagnostic accuracy for AD (O’Brien and Herholz, 2015). Whilst a positive 
amyloid scan would be expected in both early and late onset AD, some caution is necessary 
when interpreting results as increased brain amyloid occurs with advancing age (present in 
40% of the over 80’s) and possession of the ApoE4 genotype (Jansen et al., 2015), and is 
seen in around 50% subjects with DLB and in older subjects with other dementias 
(Ossenkoppele et al., 2015). 
Raised levels of CSF tau (both total and phosphorylated tau) and reduced levels of 
A-beta 1-42 have proved, when combined in a ratio, to have reasonable diagnostic accuracy 
for separating AD from other dementias (mean sensitivity 72%, mean specificity 78% when 
comparing AD to other dementias) (Mitchell, 2009). However, multi-centre studies have 
shown substantial inter-centre variation in biomarker levels, especially for A-beta 42 
(Mattsson et al., 2009), and further standardisation and investigation of the reasons for this 
are required before CSF biomarkers can enter clinical practice (Ritchie et al., 2014; Ritchie 
et al, 2015).  
 
Table 2. Summary Box:  Assessment and diagnosis 
Intervention  Level of evidence Recommendation 
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Making a diagnosis of 
dementia subtype  
 
There is type I evidence that the 
clinical diagnosis of dementia 
subtype according to internationally 
agreed consensus criteria is accurate, 
but some of the newly proposed 
criteria still require validation.  
A 
 
 
Use of structural brain 
imaging for diagnosis  
 
There is type I evidence that CT or 
MRI should be used to exclude other 
cerebral pathologies and to help 
establish the subtype diagnosis.  
A 
 There is type II evidence that medial 
temporal atrophy can be helpful in 
the diagnosis of Alzheimer’s disease, 
and for distinguishing Alzheimer’s 
disease from dementia with Lewy 
bodies in some cases. 
B 
Use of SPECT or PET 
imaging  
 
There is type I evidence that 
perfusion (HMPAO) SPECT or FDG 
PET can differentiate between 
Alzheimer’s disease, vascular 
dementia and frontotemporal 
dementia.  
A 
 There is type II evidence that FDG 
PET is superior to perfusion 
(HMPAO) SPECT in the diagnosis 
of degenerative dementia. 
B 
 There is type I evidence that 
dopaminergic SPECT or PET 
imaging can help differentiate 
dementia with Lewy bodies from 
Alzheimer’s disease. 
A 
 There is type I evidence that amyloid A 
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PET imaging can identify patients 
with elevated amyloid burden in the 
brain, and so be a useful diagnostic 
marker for Alzheimer’s disease. 
 There is type I evidence that MIBG 
can differentiate dementia with 
Lewy bodies from Alzheimer’s 
disease. 
A 
CSF biomarkers  
 
There is type II evidence that CSF 
markers of amyloid and tau may be 
useful diagnostic markers for 
Alzheimer's disease, but further 
standardization and validation is 
required before they can be more 
widely used clinically.  
B 
 
Drug treatments for Alzheimer’s disease  
Since the previous revision of the Guideline no new drugs have been licensed for AD. 
There are currently two classes of drug approved for the treatment of AD, the ChEI tacrine 
(though not marketed in the UK), donepezil, rivastigmine and galantamine and the NMDA 
receptor antagonist, memantine. Many other trials of putative disease modifying agents are 
in progress. Donepezil, rivastigmine and galantamine are licensed for mild to moderate AD, 
memantine for moderate to severe AD, and several RCTs demonstrate their efficacy in 
these situations. The drugs were originally marketed as Aricept tablets (donepezil), Exelon 
capsules and later skin patches (rivastigmine), Reminyl tablets and later Reminyl XL 
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capsules (galantamine) and Ebixa tablets (memantine); all are now available as generic or 
other marketed versions. A higher dose (13.3mg/24 hours) rivastigmine patch is now 
available (Cummings et al., 2012).  
The basic evidence to support the use of these drugs remains unchanged and, in 
general, the costs of the drugs are now significantly lower, particularly for donepezil. 
Combination therapy using a ChEI initially with the later addition of memantine is now 
considered optimal treatment in many countries particularly as the dementia advances. A 
European guideline based on systematic assessment of the quality of the evidence has been 
published and is the first such review (Schmidt et al., 2015). It suggests using a 
combination rather than a ChEI alone in patients with moderate to severe AD, but the 
strength of the recommendation is weak (see Figure 2).  
In some countries, it is recommended that ChEI treatment should stop when AD 
becomes severe and reimbursement may depend on this. There have been little data to 
guide the clinician and potential concerns have been raised that continuing treatment is 
associated with an increase in adverse outcomes (Gill et al., 2009). The UK donepezil and 
memantine in moderate to severe AD (DOMINO) study (Howard et al., 2012), which 
randomized those on stable donepezil with moderate to severe dementia (standardized 
MMSE score 5-13) to continuation donepezil, discontinuation, a change to memantine or 
adding memantine, clearly showed  that continued donepezil treatment (or a switch to 
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memantine or combination therapy)  was associated with cognitive and functional benefits 
over the following 12 months, compared to placebo  (see Figure 3). Previous data from 
observational studies as well as a more recent analysis from the DOMINO study suggest 
that treatment with anti-dementia drugs may delay admission to residential and nursing 
home care (Howard et al., 2015). 
No new comparative trials between the three ChEI, or of trials switching between 
the ChEI, have been published in the last five years. Previous comparative trials failed to 
consistently demonstrate any significant differences in efficacy between the three ChEI, the 
main differences found being in frequency and type of adverse events (O’Brien and Burns, 
2011). Similarly, our previous recommendation that a significant proportion (up to 50%) 
appear to both tolerate and benefit from switching between ChEI if they cannot tolerate 
one, remains valid. 
 
Table 3. Summary Box: Alzheimer’s disease 
Intervention  Level of evidence Recommendation 
Treatment with 
cholinesterase inhibitors 
and memantine  
There is type I evidence for the 
efficacy of cholinesterase inhibitors 
in the treatment of mild to severe 
Alzheimer's disease. 
A 
 There is type I evidence for 
memantine in moderate to severe 
A 
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Alzheimer's disease. 
 There is type I evidence that 
cholinesterase inhibitors should not 
be stopped just because the point of 
severe dementia has been reached. 
A 
Switching between 
cholinesterase inhibitors  
   
 
There is type II evidence to support 
the switching of one cholinesterase 
inhibitor to another if the first is not 
tolerated or effective. 
B 
Combination therapy   There is type I evidence for adding 
memantine to a cholinesterase 
inhibitor. 
B 
 
Drugs for dementia with Lewy bodies  
Pharmacological management of DLB remains one of the most challenging issues facing 
neurologists, psychiatrists, geriatricians, primary care physicians and others. The 
combination of cognitive, neuropsychiatric, autonomic and motor features in DLB is, when 
compared with AD, much more likely to lead to greater functional impairment and poorer 
quality of life. Moreover, the balance between these features varies, both between 
individuals and as the disease progresses. Treatments for one aspect of the disease may 
exacerbate other symptoms. In particular, treatment for neuropsychiatric features may 
exacerbate parkinsonism, while L-dopa and other antiparkinsonian medications may 
exacerbate psychosis. Careful, individualized and patient-centred approaches are required 
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to control individual symptoms, depending on the severity of symptoms and the wishes of 
patients and carers. Comprehensive reviews of the  treatment of DLB (Boot, 2015) and 
PDD (Goldman and Weintraub, 2015) and meta-analysis of trials (Wang et al., 2015; 
Stinton et al, 2015) are now available. No substantial new data regarding the use of 
antipsychotic or anti-parkinsonian drugs have been published since the previous DLB  
Consensus report (McKeith et al., 2005) and the recommendations made in these areas 
remain unchanged.  
Early RCTs of the ChEI rivastigmine demonstrated benefit in cognition in DLB 
(McKeith et al., 2000) and PDD (Emre et al., 2004) and also showed effects upon 
neuropsychiatric symptoms including hallucinations, apathy, anxiety and sleep disorders. 
New data have become available regarding donepezil in DLB (Ikeda et al., 2015; Mori et 
al., 2015) since the last BAP statement and as a result donepezil now has a marketing 
authorisation for DLB in Japan and the Philippines. All other ChEI prescribing in DLB 
remains off-label, whereas rivastigmine is licensed for use in PDD in Europe, Canada and 
the USA.  Turning to memantine, two, 24-week RCTs in people with mixed DLB or PDD 
populations (Aarsland et al., 2009; Emre et al., 2010) both showed an significant benefit on 
clinical global impression of change, but the subtype effects were inconsistent between the 
two studies, with PDD but not DLB patients benefitting in one (Aarsland et al., 2009) and 
DLB but not PDD in the other (Emre et al., 2010). Significant cognitive benefit (a 1.9 
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difference in MMSE) of memantine compared with placebo was observed in the total 
population at 24 weeks in the former, but with no significant benefit on non-cognitive 
symptoms. By contrast the latter study found cognitive improvements in only two sub-tests 
out of a 16 item battery in DLB, and none in PDD at 24 weeks. There were some 
significant improvements on the NPI, in DLB at 24 weeks but not in  PDD patients (Emre 
et al., 2010). Memantine was well tolerated in both studies Taken collectively these results 
do not show a consistent pattern of treatment response which highlights the considerable 
variation in sensitivity to treatment effects positive and negative, in this population which is 
also reported by clinicians who use ChEI. Group mean scores in trials do not fully capture 
this variability.   
After a long period without any novel pharmacological studies in patients with DLB 
there appears to be a resurgence in interest in trialling symptomatic neurotransmitter based 
compounds and it is possible that new agents will be entering the DLB armamentarium 
during the life of this guideline. 
 
Table 4. Summary Box: Dementia with Lewy bodies  
Intervention  Level of evidence Recommendation 
Cholinesterase inhibitors  There is type I evidence to support 
treatment with rivastigmine and 
donepezil in Lewy body dementias, 
both in dementia with Lewy bodies 
A 
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and Parkinson’s disease dementia. 
Memantine There is type I evidence that 
memantine produces global 
improvements in Lewy body 
dementias, both dementia with Lewy 
bodies and Parkinson’s disease 
dementia, but the pattern of 
cognitive and neuropsychiatric 
responsiveness remains uncertain.  
B 
 
Drugs for vascular and mixed dementia 
Cerebrovascular disease remains the second most common pathological cause of dementia. 
The pathologies underlying VaD are heterogeneous, ranging from large multiple infarcts 
caused by emboli to diffuse white matter changes associated with chronic hypoperfusion 
(O’Brien et al., 2003; O'Brien and Thomas, 2015 ). There are no currently licensed 
treatments for VaD within the UK, so treatment strategies have largely focused on control 
of underlying cardiovascular and cerebrovascular risk factors and treatment of associated 
symptoms. There has been a suggestion that cholinergic dysfunction occurs in VaD, 
prompting interest in the use of ChEI for this disorder. However, an autopsy-based study 
showed that loss of cholinergic function was only evident in VaD patients with concurrent 
AD and that cholinergic activity may actually be increased in those with multi-infarct 
dementia (Sharp et al., 2009), confirming an earlier report of no cholinergic loss in ‘pure’ 
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VaD (Perry et al., 2005). Cerebrovascular risk factors should be identified in all patients 
with VaD. Where prevention of recurrent stroke is necessary, use of antihypertensive 
therapy in the case of haemorrhagic stroke and use of anti-platelets or anticoagulants, 
antihypertensive and lipid lowering strategies after ischaemic stroke according to national 
guidelines should be implemented. Specific pharmacological interventions have involved 
donepezil, galantamine, rivastigmine and memantine. There is also a literature on the use of 
nimodipine, ginkgo biloba and naftidrofuryl that is discussed below. 
Since publication of the previous guideline, there have been no new studies with 
donepezil, galantamine, rivastigmine or memantine. The previous studies have been 
reviewed by Baskys and Hou (2007), Bocti et al. (2007), and Rojas-Fernandez and 
Moorhouse (2009). The studies with ChEIs show an improvement in cognition, apart from 
one study with galantamine (Erkinjuntti et al., 2002), but no overall effects in other 
measures. In one 24-week study with galantamine there were also significant improvements 
in  executive function (EXIT25) (Auchus et al., 2007). One review showed that donepezil 
produced similar changes in cognition and global function in VaD and AD but that the 
changes in VaD were inconsistent (Passmore et al., 2005). The effects of memantine in 
VaD have been reviewed by Bocti et al. (2007), Kavirajan and Schneider (2007), McShane 
et al. (2006) and Thomas and Grossberg (2009). A meta-analysis (Kavirajan and Schneider, 
2007) included all trials with donepezil, galantamine, rivastigmine and memantine 
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compared with placebo in VaD. Post-hoc analyses of the initial two donepezil studies and 
the galantamine trial suggested greater improvement in patients with cortical and multiple 
territorial lesions, respectively, compared with those with predominantly subcortical 
lesions. The authors commented that the clinical heterogeneity of VaD patients limited 
generalizability of the trials’ outcomes because the effect of treatment on specific patients 
or subgroups could not be defined. The conclusion from the meta-analysis was that ChEIs 
and memantine produced small benefits in cognition of uncertain clinical significance in 
patients with mild to moderate VaD. Data are insufficient to support widespread use of 
these drugs in VaD. Individual patient analyses are needed to identify subgroups of patients 
with VaD who might benefit.  
Nimodipine has some short-term benefits in VaD (López-Arrieta and Birks, 2002) 
and can beneficially affect MMSE, executive function measures and global rating in 
subcortical ischaemic vascular dementia (SIVD) (Pantoni et al., 2005). However, there has 
been no update on the original Cochrane review of nimodipine (López-Arrieta and Birks, 
2002) and there remains a need for longer duration studies. In this context, rivastigmine (up 
to 6 mg daily) was compared with nimodipine in a single-blinded study of 14 months 
duration. Patients were subdivided according to whether they had multi-infarct dementia 
(MID) or SIVD. In the SIVD group rivastigmine did not improve MMSE but had beneficial 
effects upon measures of executive function, neuropsychiatric features, depression and 
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Clinical Dementia Rating. In the MID group, rivastigmine had no effect on MMSE, but had 
beneficial effects on neuropsychiatric features and depression. All patients in the 
rivastigmine groups completed the study (Moretti et al., 2008).  
Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leucoencephalopathy (CADASIL) is a rare monogenetic form of SIVD. In an 18-week, 
placebo controlled double-blind, randomized parallel-group trial, 10 mg donepezil daily 
had no effect on V-ADAS-Cog (the primary outcome measure) but there was a significant 
treatment effect favouring donepezil on some measures of executive function, the clinical 
relevance of which was unclear (Dichgans et al., 2008).  
There have been further studies with ginkgo biloba (EGb761®). These have been 
reviewed by Baskys & Cheng (2012) and Gauthier & Schlaefke (2014) and studies 
included  patients with AD, VaD or mixed dementia (Wang et al., 2010; Weinmann et al., 
2010) but no data related to VaD alone has been provided. One RCT separately analysed 
the efficacy of EGb761® on 71 patients with VaD (Ihl et al., 2012). EGb761® treatment 
was superior to placebo in patients with VaD with respect to the Short Cognitive 
Performance Test and Neuropsychiatric Inventory scores. In a systematic review (von 
Gunten et al., 2015) of patients with dementia and mild to moderate behavioural symptoms, 
it was reported that EGb761® at a dose of 240mg had significant benefits on cognition, 
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activities of daily living, behavioural symptoms, clinical global impression but not quality 
of life in the VaD subgroup. Further studies are recommended. 
A Cochrane review of Huperzine A (a naturally occurring cholinesterase inhibitor 
derived from the Chinese herb Huperzia serrata) concluded that there is no convincing 
evidence that Huperzine A is of value in VaD. This was based on one small trial and further 
research is needed (Hao et al., 2009).  
In a recent Cochrane review of naftidrofuryl (Lu et al., 2011), the conclusion was 
that in patients with VaD or mixed dementia there were significant benefits on a number of 
outcomes. However the numbers were very small and did not permit an overall 
recommendation apart from the need for further trials in specific groups. 
It is widely recognised that a good number of people diagnosed with dementia have 
mixed brain pathology which is predominantly due to Alzheimer’s and cerebrovascular 
changes. One RCT with galantamine (Erkinjuntti et al., 2002) included VaD and AD 
patients showing radiological and historical evidence of  cerebrovascular disease. A 
combined analysis of VaD and AD patients showed a significant treatment effect on 
cognition, function, behavioural symptoms and clinical global impression. The systematic 
review of EGb761®reported significant benefits in all outcomes tested in patients with 
mixed dementia. Further studies are necessary in well defined groups. 
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There is a rationale for study of vascular risk factor control in established mixed 
dementia. In a recent randomized controlled trial, multi-component vascular care that 
combined pharmacological and nonpharmacological interventions did not slow functional 
or cognitive decline in 130 patients with AD and CVD (Richard et al., 2009). However it is 
worth noting that some of the vascular factors, for example blood pressure, were no 
different between the intervention and control group.  
 
Table 5. Summary Box: Vascular dementia  
Intervention  Level of evidence Recommendation 
Treatment with 
cholinesterase inhibitors 
and memantine  
 
There is type I evidence showing 
small cognitive improvements with 
both cholinesterase inhibitors and 
memantine in vascular dementia. 
However, benefits in terms of global 
outcome are not seen and adverse 
events for cholinesterase inhibitors 
(but not memantine) are significantly 
greater than placebo. Evidence 
indicates that neither cholinesterase 
inhibitors nor memantine should be 
prescribed to people with vascular 
dementia, though those with mixed 
vascular dementia and Alzheimer’s 
disease may benefit. 
A 
 
Other dementias 
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This group of disorders is used here to include FTD, the Primary Progressive Aphasias, 
Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBD) and prion 
dementias amongst others, and the overlap between some of these conditions is illustrated 
in Figure 4. No new evidence regarding the use of ChEI in FTD has become available since 
the last BAP statement. The existing evidence does not support the use of these drugs in 
FTD although rates of off label use remain high, despite increased agitation having been 
reported with their use in FTD (O’Brien et al, 2011). There have been no new trials of 
antidepressants in FTD, as before, evidence for the use of these drugs is mixed and largely 
rests on small open label studies. New randomized controlled trials of memantine in FTD 
report a lack of efficacy with this drug (Boxer et al., 2013; Vercelletto et al., 2011). A small 
trial of Souvenaid reported beneficial effects in behaviour and social cognition measures 
over a short time period (Pardini et al., 2015), but more studies are needed. Oxytocin 
administered intranasally in FTD appears safe and tolerable; larger studies are needed to 
assess its efficacy (Finger et al., 2015).  
There are no adequately powered treatment studies in Primary Progressive Aphasia 
upon which to make firm recommendations. Since the last BAP statement there has been no 
new trial evidence for ChEI or Coenzyme Q10 in treating PSP. Existing evidence does not 
support their use. The largest PSP trial to date found that davunetide (proposed to decrease 
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tau phosphorylation and stabilize microtubules) was not an effective treatment (Boxer et al., 
2014).  
Since the last BAP statement a trial demonstrated no survival benefit in Creutzfeldt-
Jakob disease (CJD) patients treated with quinacrine (an antimalarial drug that reduces 
abnormal prion protein deposits in vitro) (Geschwind et al., 2013). Doxycycline was not 
effective in treating CJD (Haïk et al., 2014). 
There are no adequately powered studies of ChEI to support the use of these drugs 
for cognitive impairment in Huntington’s disease. There is no evidence to support the use 
of other medications to treat dementia associated with Huntington’s disease though several 
disease modifying avenues are being pursued, including compounds to reduce metal 
induced aggregation of the Huntingtin protein (Angus et al., 2015). 
 
Table 6. Summary Box: Frontotemporal dementia 
Intervention  Level of evidence Recommendation 
Cholinesterase inhibitors There is type I evidence that 
cholinesterase inhibitors are not 
recommended for the treatment of 
frontotemporal dementia. 
A 
SSRIs There is type II evidence that SSRIs 
may help some behavioural aspects 
of frontotemporal dementia, but do 
not improve cognition. Studies are 
mixed and further evidence is 
B 
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needed. 
Memantine There is type I evidence that 
memantine is not recommended for 
frontotemporal dementia. 
A 
 
Table 7. Summary Box: Progressive Supranuclear Palsy 
Intervention  Level of evidence Recommendation 
Progressive supranuclear 
palsy 
Type II evidence indicates that no 
treatments can be recommended at 
the current time. 
B 
 
Mild cognitive impairment, MCI due to AD and Prodromal 
Alzheimer’s disease 
There have been no new positive studies to inform prescribing in prodromal conditions 
such as mild cognitive impairment (MCI). Cochrane and other reviews show lack of 
efficacy of ChEI (Birks and Flicker, 2006; Loy and Schneider, 2006), equivocal findings 
with piracetam (Flicker and Grimley Evans, 2001) and there is no other evidence to support 
nootropics. There have been no studies of memantine in MCI. Other studies including 
RCTs of vitamin E and anti-inflammatory drugs (rofecoxib) have been negative. There 
have been numerous trials conducted and ongoing in MCI due to AD or prodromal AD 
though none have been successful and progressed beyond Phase 3. 
 
31 
 
Table 8. Summary Box: Mild cognitive impairment  
Intervention  Level of evidence Recommendation 
Treatment with  
cholinesterase inhibitors 
and vitamin E 
There is type I evidence that 
cholinesterase inhibitors are not 
effective in reducing the risk of 
developing Alzheimer’s disease and 
type I evidence that vitamin E is not 
effective in reducing the risk of 
Alzheimer’s disease.  
 
There is type 1 evidence that 
cholinesterase inhibitors are not 
effective in those with Mild 
Cognitive Impairment 
A 
 
 
 
 
 
A 
 
Other relevant issues in management 
The NICE process  
In the UK, within England and Wales, recommendations on the use of licensed 
drugs are made by the National institute for Health and Clinical Excellence (NICE). NICE 
was established in 1999 as a NHS Special health Authority and changed in 2013 to an 
arm’s length non-departmental government body. This reflected an extension of its remit to 
also include social care. It is contained within the Department of Health but outside the 
NHS and it is accountable to parliament through the Secretary of State for Health. It has 
several remits, including the production of focussed technology appraisal, mostly on drugs, 
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and broader guidelines which can cover clinical care, public health and social care. With 
regard to dementia, there have been several technology appraisals on anti-dementia drugs, 
the most recent (TA 217) on ChEI and memantine for AD, published in 2011 and updated 
2016. Unlike earlier technology appraisals of these drugs, which had limited use of these 
agents to either those who were deemed to respond to the drug or to those with moderate 
disease, TA 217 recommends the use of donepezil, galantamine and rivastigmine as 
treatment options for all patients with mild to moderate AD, and memantine for moderate 
to severe AD. No recommendations are made either for or against combined therapy. 
Recommendations for severe disease or for non-Alzheimer dementia are not contained 
within TA 217, since technology appraisals are limited to the licence of the drug. 
There is also a NICE dementia guideline, GD42 (NICE, 2006), which was in the 
process of being fully revised at the time of the publication of this BAP guideline. The 
current guideline recommends the use of ChEI for Lewy body dementia, but not for FTD, 
VaD or MCI.  
 
Perspective from a person with dementia 
Many people with dementia and their carers have been important advocates for the 
clinical use of anti-dementia drugs and this should be an essential part of any decision 
making process. As with previous guidelines, for this revision we invited Peter Mittler as a 
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person with dementia to join the meeting. His insights were invaluable and very much 
accorded with experience of the clinicians on the panel. Peter reflected on the wider 
contexts in which the first prescription can be considered. These range from the patient’s 
initial interpretation of the significance of medication to the ethical imperative for 
professionals to strike a balance between the global quest for cure and the fundamental 
human rights of people with dementia for care and supporti.  This is consistent with the bio-
psychosocial model of impairment which includes quality of life indicators.    
Accounts provided by people living with dementia reflect strong dissatisfaction with the 
complex journey to diagnosis and also with the lack of post-diagnostic support (Schalock et 
al., 2016). These suggest that the time is ripe for clear guidance on good and bad practice in 
diagnosis and its aftermath.  The medical profession carries the main responsibility for 
timely diagnosis and for maintaining the health and well-being of each person in their own 
homes for as long as possible. It is well placed to use its prestige with the public to 
emphasise that disability is part of the human experience and that it is possible to live well 
with dementia. It could also influence public opinion, politicians and the media by avoiding 
the use of degrading language involving time-bombs and tsunamis.  In our quest for 
prevention and cure, we have lost sight of the uniqueness of the individual highlighted by 
Tom Kitwood and more recently by Steven Sabat who focuses on the maintenance of a 
sense of self and personal identity from first diagnosis to the end of life (Schalock et al., 
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2016).  We need to provide services based on the needs and wishes of the individual and 
their principal care partner by providing tailor-made support and rehabilitation comparable 
to that received by people who sustain brain injury as a result of stroke or road traffic 
accident. A visiting dementia adviser should be able to access the additional supports that 
are or may become necessary – e.g. an occupational therapist to suggest adaptations to the 
home and to appliances such as personal computers.  A dementia-friendly community 
should include children, young people and students, who as future leaders need to be aware 
that each person with dementia is a unique individual with the right to be supported as a 
member of their local community. 
  
The role of Primary Care in the management of dementia 
Primary care general practitioners (GPs) increasingly work in larger 
multidisciplinary teams.  This expansion has been influenced by a national policy of care 
closer to home, greater focus on preventative care and the transfer of primary clinical 
responsibility for chronic disease management from secondary to primary care.  Most 
common chronic illnesses (e.g. diabetes, asthma, hypertension) are largely managed by the 
GP with the aid of shared care pathways, prescribing protocols and specialist nurses.  A 
new General Medical Services (GMS) Contract in 2004 fundamentally changed the way 
GPs in England work through the introduction of ‘core services’ with ‘optional enhanced 
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services’.  The Contract links achievements in care quality, with a major focus on chronic 
illness care, properly funded through an evidence-based Quality and Outcomes Framework 
(QOF). QOF criteria for dementia exist and comprise: i). establishing and maintaining a 
register of patients with diagnosed dementia and ii) undertaking an annual review on 
patients’ on the register.  
The majority of people with dementia live in the community with their GP the 
primary health care provider most of the time.  The GP can have an extensive range of post 
diagnostic responsibilities including: information provision; access to other services; carer 
support; management of co-morbid conditions and behavioural problems; future care 
planning and end of life care (Robinson et al., 2010). As our populations rapidly age and 
the demand on specialist old age psychiatry services increases, primary care may need to 
undertake a more formalised shared care approach to dementia care as has existed in 
diabetic care for the last twenty years.  A recent RCT comparing the effectiveness of 
memory clinics and GPs for delivery of post diagnostic care found no significant 
differences between the two services (Meeuwsen et al., 2012). 
In some European countries GPs can initiate anti-dementia drugs; the current 
evidence base for the initiation, and review, of anti-dementia drugs by non-specialists is 
very limited and restricted to low quality, observational studies (Aupperle and Coyne, 
2000; Aupperle et al., 2003; Watanabe et al., 2012).  In the UK existing NICE guidelines 
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(2006) stipulates drug initiation should be on the advice of a specialist, with shared care 
prescribing supported for maintenance treatment.  A UK pilot trial of a GP educational 
prescription to support dementia diagnosis and improve quality of care found that GPs had 
little knowledge of shared care protocols for anti-dementia drugs, with specialists still 
largely responsible for monitoring (Wilcock et al., 2013).  However a US based trial of a 
care manager intervention, combined with a quality improvement/professional education 
component, found increased anti-dementia drug prescribing in primary care (Vickrey et al., 
2006).  With specialist disease nurses, key to the success in chronic illness management in 
primary care, the role of a nurse dementia case manager affords considerable potential for 
person-centred post diagnostic care.  The evidence base however is mixed with a recent UK 
pilot trial struggling to successfully integrate dementia case managers into existing NHS 
primary and community care services  (Bamford et al., 2014).  New alternative primary 
care models with GP-led memory clinics and attached nurse facilitators have been 
established in some areas.  
In summary, the current system of shared care prescribing of anti-dementia drugs in 
the UK requires further evaluation in order to identify facilitators to improve care quality. 
With regard to GP-led prescribing, this will be influenced by the revised NICE guidelines 
(due 2017); such a change in practice would however require upskilling of GPs, prescribing 
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protocols and the development of a shared care, integrated system co-ordinated by possibly 
specialist nurses.   
 
Table 9. Summary Box: Primary care  
Intervention  Level of evidence Recommendation 
Initiation and 
prescription of anti-
dementia drugs 
There is type IV evidence to support the current 
practice of non-specialist initiation of these 
drugs, following a specialist diagnosis. 
D 
 There is type II evidence indicating no 
significance differences between the ongoing 
prescription and monitoring of the drugs 
between memory clinic and GP-led services. 
B 
 
 
End of life Care 
One third of older people will die with some form of cognitive impairment or 
dementia (Brayne et al., 2006). There are two populations of people with dementia for 
whom end of life care needs to be considered, those who have dementia in the in early-
moderate stages but are dying from other disease such as cancer or organ failure or those 
who have advanced dementia where the commonest cause of death is pneumonia or other 
infection. They may experience poor end of life care because they are often not perceived 
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to have a terminal illness and health and social care services may not be optimally 
configured to meet their complex needs (Sampson et al., 2011). 
In people with advanced dementia the main prescribing decisions are related to 
considering the “ceiling of care”. Thus stopping medications which may have no longer 
term benefit i.e. statins, low dose aspirin or anti-hypertensives may be appropriate (Holmes 
et al., 2008).  
There is little evidence available on how best to prescribe for people with severe 
dementia, particularly when to stop drugs which are no longer necessary or beneficial. 
There is a lack of RCT data for anti-dementia drugs in this population. Trials tend to be for 
short periods of 3-12 months with open-label extension studies after this and there is little 
evidence for continuing treatment when people reach this stage. It has been argued that the 
prescription of ChEI or memantine is “never appropriate” towards the end of life although 
their use remains common in care home residents (Holmes et al., 2008). However, in 
patients with moderate or severe Alzheimer's disease, continued treatment with donepezil is 
associated with significant functional benefits over 12 months; thus continuing a 
cholinesterase inhibitor may be in-keeping with a palliative approach (level I 
evidence)(Howard et al., 2012)(see Figure 2). There is uncertainty over the efficacy of 
memantine in end-stage dementia and the most appropriate time to discontinue this.  
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Different formulations and modes of administration, for example ChEI delivered as 
patches should be considered. The use of anti-dementia drugs should be balanced with the 
risk of side effects, for example Memantine may worsen constipation associated with 
analgesics; polypharmacy is a key issue. Covert medication may be in the person’s best 
interests if conducted within the correct ethical and legal frameworks.  
Analgesics tend to be under prescribed in people with advanced dementia but 
concerns about polypharmacy, interactions and side effects can be addressed. The most 
commonly used analgesic is paracetamol although studies using the WHO analgesic ladder 
which advances to NSAIDS and opioids show this approach improves pain and 
neuropsychiatric symptoms (level II evidence)(Husebo et al., 2011).   
There is little strong evidence on prescribing in people with dementia who are 
reaching the end of life (level III only). Clinicians should take into account individual 
preferences of the person with dementia, if known, and their families, and aim to achieve 
the best symptom control and quality of life. 
 
Table 10. Summary Box: End of Life Care  
Intervention  Level of evidence Recommendation 
Withdrawal of anti-
dementia drugs 
There is type I evidence that continuing 
donepezil may decrease the rate of functional 
decline in moderate/severe dementia. There is 
C 
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type III evidence that it may be inappropriate to 
prescribe memantine and cholinesterase 
inhibitors in advanced dementia towards the 
end of life. 
 
Other putative therapies for dementia 
Dimebon (latrepirdine) is an antihistamine identified as a weak inhibitor of cholinesterase 
activity with a number of other actions, including enhancing mitochondrial function. At the 
time of the previous guideline, a single randomised placebo controlled trial of 183 people in 
Russia showed benefits of dimebon treatment over placebo (Doody et al., 2008). 
Unfortunately other studies have not been able to replicate these findings and a recent 
Cochrane review (Chau et al., 2015) concluded there was no beneficial effect of dimebon 
on cognition in AD, though did not rule out a possible benefit on behaviour.   
 
Gingko biloba 
Early trials were small, of poor quality and raised concerns about publication bias 
but two large well designed RCTs in dementia subjects (McCarney et al., 2008; Schneider 
et al., 2005) showed no benefits from Gingko on cognition. A primary prevention 
feasibility study (Dodge et al., 2008) over 42 months in 118 people over 85 at baseline 
found gingko biloba did not prevent the development of dementia or decline in memory but 
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found an increase in stroke and TIA cases in the gingko group and the GEM Study 
(DeKosky et al., 2008) assessed 3069 volunteers who had MCI or were cognitively normal 
randomised to placebo or ginkgo biloba over a median follow-up of 6.1 years. Gingko had 
no effect on reducing incident Alzheimer’s disease or all-cause dementia but was associated 
with a non-significant doubling in haemorrhagic stroke (16 vs 8). However, a meta-analysis 
(N=1985, mainly people with dementia) of the effect of gingko on coagulation found only 
small and clinically insignificant changes (Kellermann and Kloft, 2011). 
 
Hormone replacement therapy 
A large primary prevention trial, the WHIMS trial (the Women’s Health Initiative 
Memory Study) examined the possible benefit of HRT/ERT in reducing dementia in post-
menopausal women (participants were 65-79 at entry). Adverse outcomes led to both arms 
being terminated early. The use of unopposed oestrogen (N=1464 vs N=1483 on placebo) 
for about 7 years was associated with a non-significant increased risk of dementia, hazard 
ratio 1.49 (95%CI 0.83-2.66) (Shumaker et al., 2004), and treatment with combined 
oestrogen and progestin for about 4 years (N=2229 vs 2303 on placebo) led to a doubling 
of dementia risk, hazard ratio 2.05 (95%CI 1.21-3.48)(Shumaker et al., 2003). Combining 
these two groups, there was a highly clinically and statistically significant increase in 
dementia in women taking HRT, hazard ratio 1.76 (95%CI 1.19-2.60)(Shumaker et al., 
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2004). Following WHIMS the critical window hypothesis emerged claiming use of ERT in 
younger women might be beneficial but a recent review has questioned this and there is no 
good quality data to support this (Maki and Henderson, 2012). 
 
Folate and vitamin B12 
Dietary supplementation using folic acid (synthetic analogue of folate) and vitamin 
B12, which reduce homocysteine levels, have been proposed for preventing and treating 
dementia. Whilst cross-sectional studies have generally supported this view (Ho et al., 
2011), prospective studies have not found a relationship between dementia and high 
homocysteine (Ho et al., 2011) and a systematic review of randomised clinical trials of B 
vitamin and folate supplementation found no beneficial effects on cognition in people with 
or without cognitive impairment (Ford and Almeida, 2012).  
 
Statins and dementia  
No new randomised placebo controlled trials in relation to dementia prevention 
have been published since the last guideline. Neither of the previous two large studies 
(heart protection study and PROSPER) found an effect of statins on ameliorating cognitive 
decline or dementia. 
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Souvenaid 
Three double blind RCTs with a medical food (nutritional combination Fortasyn 
Connect) in AD have been reported. Souvenir I and II were in people with mild AD 
(MMSE ≥20) not on AD medication. Souvenir I (Scheltens et al., 2010), in 212 subjects 
randomised to active drink or control drink, found a small improvement in a categorical 
analysis of the WMS-R delayed recall at 12 weeks but not in overall change in WMS-R 
delayed recall or in ADAS-Cog or other outcomes or in any measures at 24 week extension. 
Souvenir II (Scheltens et al., 2012) found a small improvement at 24 weeks in the 
Neuropsychological Test Battery memory composite score in 209 subjects but not in 
overall score or in any other outcome measures. The S-Connect study (Shah et al., 2013) in 
527 people with mild to moderate AD (MMSE ≥14) on AD medication found no 
improvements in the active group in the primary outcome (ADAS-Cog) at 24 weeks or in 
any other clinical measures. The drink was well tolerated in all studies. The absence of any 
evidence of benefits on global outcomes and only patchy modest effects on memory scores 
do not provide evidence to support its use in AD.  
 
Therapeutic non-invasive brain stimulation 
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Interest in the use of non-invasive stimulation approaches such as transcranial direct 
current stimulation (tDCS) and rapid rate transcranial magnetic stimulation (rTMS) has 
gained significant traction over the past number of years. The use of such approaches is 
appealing in dementia given their low predilection to side effects and evidence across 
multiple investigative platforms (e.g. young healthy controls, ageing studies, pathological 
groups etc.) has suggested that non-invasive stimulation techniques can have effects which 
are sustained beyond the period of the stimulation and this clearly has important therapeutic 
ramifications (Elder and Taylor, 2014; Hsu et al., 2015; Kuo et al., 2014). 
rTMS, in particular, is now used for a wide array of neurological and mental health 
symptoms; for example rTMS is now a US Food and Drug Administration (FDA) approved 
treatment for Major Depressive Disorder in patients who have not responded to prior 
antidepressants (US Food and Drug Administration, 2011) and guidance on its use for 
conditions such as depression and migraine have been issued by the UK National Institute 
for Clinical Excellence (NICE, 2014, 2015). 
Mechanistically both tDCS and rTMS modulate cortical activity non-invasively. 
rTMS does so by the delivery, through the scalp, of a high intensity time-varying magnetic 
pulse which causes current flow within the brain. By varying the stimulation parameters 
such as the stimulation intensity, frequency of pulsing and duration, rTMS can either 
enhance or suppress cortical activity in target brain regions. tDCS delivers a low intensity 
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electrical current, typically between two scalp pads (positive polarity= anode; negative 
polarity = cathode) and has been postulated to modulate neuronal transmembrane potential 
toward hyperpolarization or depolarization in brain tissues underlying the anode or cathode 
scalp pads, respectively. 
Non-invasive brain stimulation techniques have been applied in healthy older adults 
to enhance cognition and importantly, also in patients with dementia (Boggio et al., 2011; 
Hsu et al., 2015) but the data are not as comprehensive as that for the treatment of 
depression with rTMS. A recent systematic review and meta-analysis identified 11 studies 
with a total of 200 Alzheimer’s disease patients and found a significant effect size of 1.35 
for cognitive outcomes with subgroup analyses suggesting more pronounced effects for 
studies applying the stimulation during the execution of a cognitive task compared with 
studies delivering the stimulation before the task (Hsu et al., 2015). However there was 
very little data to indicate whether any cognitive benefits are sustained. In addition, it was 
noted in the meta-analysis by Hsu et al. (2015) that individual trial sizes were small and 
protocol designs heterogeneous; furthermore in the studies examined there was also 
evidence of positive publication although notably across the dementia studies which 
examined rTMS or tDCS there was a lack of any serious adverse events. 
Quality trial data for the use of rTMS or tDCS in other dementias is even more 
scant (Elder and Taylor, 2014). Similarly extension of the use of these non-invasive 
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approaches to ameliorate neuropsychiatric symptoms in dementia is very limited and 
positive outcomes uncertain; for example, one double blind RCT of tDCS for the treatment 
of apathy in 40 AD subjects did not demonstrate any positive effect (Suemoto et al., 2014).  
There are also controversies about the efficacy of tDCS and general issues of 
concerning the design of tDCS protocols which have hampered development of robust and 
well powered trials (Elder and Taylor, 2014; Horvath et al., 2014, 2015). 
Therefore, it is too soon to formally recommend these approaches in their 
application to the treatment of dementia and its associated symptoms although the existing 
data may suggest that there may be a potential future role for these agents but further larger 
scale and well-designed trials are needed. 
 
Table 11. Summary Box: Other treatments for dementia  
Intervention  Level of evidence Recommendation 
Hormone Replacement 
Therapy (HRT) in 
prevention and treatment of 
Alzheimer’s disease in post-
menopausal  women 
There is type I evidence that HRT is 
not effective either in treating 
cognition in Alzheimer’s disease, or 
for the primary prevention of all-
cause dementia or Alzheimer’s 
disease. 
 
A 
 There is type I evidence that HRT is 
harmful. HRT should not be 
prescribed either as a prevention or 
treatment for dementia, including 
A 
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Alzheimer’s disease. 
Folate and vitamin B12 for 
dementia  
There is type I evidence that 
supplementation with folic acid with 
or without vitamin B12 does not 
benefit cognition in people with 
dementia. On current evidence, 
neither vitamin B12 nor folate, either 
singly or in combination, can be 
recommended as treatments for 
dementia, or for dementia 
prevention. 
A 
Statins for the treatment or 
prevention of dementia 
There is type I evidence that statins 
do not prevent dementia.  
A 
 There is type II evidence that statins 
do not produce cognitive benefits in 
Alzheimer’s disease. 
B 
 
Souvenaid 
There is type II evidence indicating 
possible benefits of Souvenaid on 
cognition but effects are variable 
between studies and no effect on 
global outcomes has been shown. 
Souvenaid is not recommended until 
further evidence becomes available. 
B 
rTMS and tDCS There is type II evidence indicating 
benefit of rTMS and tDCS on 
cognition but effects may not be 
sustained. These treatments are not 
recommended until further evidence 
becomes available. 
B 
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Disease modifying therapies  
There are several strategies currently being investigated for possible disease modifying 
effects in people at high risk of progression to dementia, though most studies focus on AD 
and include subjects with prodromal AD or preclinical AD. These include the use of drugs 
that may modulate amyloid and/or tau processing, e.g. to decrease production of beta 
amyloid or to increase its breakdown or removal, and other approaches which try to reduce 
the likelihood of amyloid monomers binding to produce oligomers and insoluble sheets. 
There have also been anti-inflammatory and neurotrophic strategies.  
 
Immunisation 
The success of mouse vaccine studies led to the first human trials of an active Aβ 1-
42 vaccine (AN1792) in people with AD. Neuropathological examination of subjects from 
a phase I RPCT of AN1792 showed variable removal of amyloid plaques and no impact on 
long term clinical outcomes. A large phase II RPCT also failed to show clinical efficacy. In 
addition, 6% subjects developed meningo-encephalitis.  More recently, the development of 
another active immunisation approach, CAD106 (Aβ 1-6), has shown sustained Aβ 
response and long term safety in AD but clinical data have not been fully reported. 
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A number of passive immunisation approaches have been tried in AD (see Figure 
5). Bapineuzumab (anti  Aβ 1-5) showed no evidence of clinical efficacy in phase II studies 
and around 10% subjects developed  vasogenic oedema.  An exploratory analysis showed 
better clinical outcomes in patients who did not carry the APOE e4 allele which led to two 
large RPCT’s of Bapineuzumab in APOE e4 positive and negative AD subjects (Salloway 
et al., 2014).  Neither study showed beneficial clinical effects. Solanezumab (anti Aβ 13-
28), aimed at soluble monomeric Aβ, failed to show overall clinical benefit in two large 
phase III studies of AD.  Likewise, Crenezumab (anti  Aβ 12-23), aimed at aggregated Aβ, 
failed to show clinical benefit in a large phase II study. Retrospective analysis of the 
Solanezumab and Crenezumab data has led to larger studies aimed at the mild AD cohort.  
Aducanumab (anti Aβ 3-6) has shown effective amyloid removal but with mixed clinical 
outcomes and marked side effects with increasing dose.  Gantenerumab (anti  Aβ 1-11), has 
specifically a priori examined very early AD (cognitively normal but amyloid positive 
PET).  Unfortunately this 2 year RPCT study showed no efficacy on primary or secondary 
outcomes.  
A number of these active or passive immunisation approaches  are now being tested 
in long term preventative RPCT studies of APOE e4 positive, cognitively normal subjects 
(CAD106) or presymptomatic carriers of early onset AD mutations (Solanezumab, 
Crenezumab and Gantenerumab). Finally the use of pooled human plasma antibodies 
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Gammagard™ has been examined in a phase III RPCT trial of AD patients with no 
differences found on primary outcomes. It is worth noting that of the other anti-amyloid 
approaches the use of β secretase inhibitors are still in active development and there is 
increasing interest in immunisation approaches aimed at the prevention of tangle 
propagation.  
 
Anti-inflammatory approaches 
A large number of RCT’s of anti-inflammatory agents in AD have failed to reach 
primary outcomes (Heneka et al., 2015). Large scale studies of NSAIDs including 
indomethacin, naproxen and rofecoxib in AD have been unsuccessful.  RPCT’s with a 
range of other anti-inflammatory drugs, including prednisone, hydroxychloroquine, 
simvastatin, atorvastatin, aspirin and rosiglitazone have also shown no clinically significant 
changes in primary cognitive outcomes in patients with AD. A small RPCT of etanercept 
showed some evidence of a reduction of clinical decline but it has yet to be replicated in a 
large scale study (Butchart et al., 2015).  Epidemiological studies of the protective effects 
of NSAID’s are generally more positive. However, RPCT’s examining the possible 
protective effects seen in these studies are mixed. Thus a large trial of rofecoxib found an 
increased risk of conversion to AD in the MCI treated group (Thal et al., 2005). Likewise a 
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large randomised study of the NSAIDs naproxen and celecoxib in asymptomatic 
individuals with a family history of AD initially reported an increased risk of increased 
cognitive decline for both drugs. However, a longer-term follow-up of these patients 
suggests that the early detrimental effects were mostly in a small group of patients with 
early cognitive impairment and naproxen seemed to be protective in patients for up to 4 
years in those who had been asymptomatic at baseline (Alzheimer’s Disease Anti-
inflammatory Prevention Trial Research Group, 2013). 
 
Table 12. Summary Box: Disease modifying therapies  
Intervention  Level of evidence Recommendation 
Gamma secretase inhibition There is type I evidence that gamma 
secretase inhibitors are not effective 
in Alzheimer’s disease. 
A 
 There is type I evidence that 
tarenflurbil is not effective in 
Alzheimer’s disease. 
A 
Vaccination and 
immunization 
studies 
There is preliminary type II evidence 
of their effect in Alzheimer’s disease 
on some endpoints, but also type II 
evidence that amyloid lowering does 
not affect clinical course. Amyloid-
lowering agents should not be 
prescribed until the optimal disease 
stage, safety and efficacy data are 
available. 
B 
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Optimising outcome measures for trials 
Following the expansion of NHS Memory Services, the number of people 
diagnosed with dementia in the UK has increased hugely (Mukadam et al., 2014), so that 
around 100,000 people per year receive a diagnosis of AD within the NHS.  There have 
been huge strides forward in managing dementia. These include  early diagnosis, 
information, advance decision making, cognitive stimulation therapy, management of 
neuropsychiatric symptoms, strategies for family carers, ChEI in Alzheimer’s disease (AD) 
and changes in attitudes, including highlighting personhood and living well with dementia, 
but there is no cure or disease modifying treatment for the common dementias (Prince et 
al., 2011).   
Currently trials of drugs for disease-modification in AD use different outcomes eg 
MRI brain volume change or change in cognition or function. They also use differing 
measures of the same outcome. Use of an agreed set of the most valid trials’ outcome 
measures for disease modification studies would improve efficiency and enhance 
interpretation of data across studies (Ghezzi et al., 2013). This would allow the comparison 
of the efficacy of both drugs and non-pharmacological interventions, for example, exercise, 
cognitive stimulation and new drugs.  Standardised core outcomes would also aid meta-
analysis and enable small data sets to be combined and inform practice. These may include 
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quality of life and related outcomes, that people with dementia and their families report as 
being important to them, and can also inform cost-effectiveness analysis. 
In the HTA funded Core Outcomes in Dementia study (COD dementia), we have 
brought  together a wide body of NIHR dementia researchers to debate and agree on the 
best outcome measures for  future clinical trials in mild and moderate dementia and expect 
our conclusions will have international impact and shape and optimise the design of future 
dementia trials.  
 
Prospects for prevention  
Prevention is typically considered in three main subdivisions. Primary prevention is where 
the onset of disease is prevented. Secondary prevention is where clinical symptoms are 
prevented in people with evidence of disease and tertiary prevention is where a later stage 
of clinical progression is prevented in people with both disease and symptoms. As can be 
seen from this general description, the terms are dependent upon the definitions of ‘disease’ 
and ‘symptoms’. When we refer this to the case of AD, it is therefore critical to draw a 
distinction between AD and AD dementia.  
In this regards, the secondary prevention is ‘of’ a clinical condition so – for instance 
in the EPAD (European Prevention of Alzheimer’s Dementia) Project (Ritchie et al., 2015), 
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the title implies that the project is seeking to prevent dementia and hence encompasses (in 
the case of secondary prevention) intervening in populations who have evidence of AD and 
are either preclinical (disease and no symptoms) or prodromal (disease and symptoms but 
not satisfying criteria for dementia).  
Despite billions of dollars of effort, there are no drugs available that achieve 
secondary prevention of dementia (Schneider et al., 2014). Non-pharmacological, multi-
modal interventions have shown better evidence of success than any drug to date e.g. the 
FINGER study (Ngandu et al., 2015). Pharmaceutical interventions have been hampered by 
poor definitions of the target population with inadequate stratification of risk and sample 
heterogeneity, inadequate psychometric properties of outcome measures, interventions 
being applied at a very late stage of the disease process, absence of surrogate biomarker 
changes for clinical changes and sub-optimal study prosecution. Moreover, in a complex 
disorder like Alzheimer’s disease, specific interventions against single disease processes 
are unlikely to yield benefit if multiple pathological processes contribute to the clinical 
phenotype.  
The basis therefore for successful secondary prevention of Alzheimer’s dementia 
therefore needs all these historical shortcomings to be addressed. That is we need to 
develop much better disease models in preclinical and prodromal dementia that will 
underpin stratification of populations into more predictable groups for progression and we 
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need to map onto this population clinical outcomes. These outcomes need to reflect changes 
to the underlying disease process from an experimental neuropsychology perspective 
forwards rather than a dementia outcomes foundation backwards.  We need to intervene as 
early as possible on the basis of these disease models and accept outcomes that are 
surrogates for incident dementia. We also need mechanisms to undertake combinatorial 
trials of agents with different pathological or mechanistic targets. Finally, the trials 
themselves need to be conducted in a limited number of centres with access to the target 
populations to run at scale and maintain data quality and reduce sample heterogeneity. The 
EPAD program concurrently addresses all these elements. 
In conclusion, the secondary prevention of dementia is reliant heavily on a more 
complete understanding of the neurodegenerative disease processes, which lead to clinical 
symptoms and eventually dementia. This means we need to undertake projects (e.g. EPAD 
and PREVENT (Ritchie and Ritchie, 2012) which can measure brain changes through 
biomarker development of disease processes in mid-life beyond amyloid and tau pathology 
to be able to incorporate (for example) inflammatory, cerebrovascular, HPA Axis and other 
protein mis-folding (e.g. Prion and α-synuclein disease). Until such models are developed 
and used, we will be continuing to run trials that are making too many assumptions and 
therefore taking too much risk and may only succeed through serendipity rather than by 
design. Because of this, it may be that multimodal interventions that include interventions 
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that target broad risk factor modification e.g. diet and optimised cardiovascular health may 
prove more successful.  
Currently, there is no evidence for pharmacological intervention to prevent 
dementia. There is Level 1 evidence from an RCT that met its primary outcome that a 
combination of diet, cognitive training, cardiovascular health optimisation and exercise can 
slow cognitive decline in an at-risk elderly population (Ngandu et al., 2015), though the 
contribution of each factor within the FINGER multi-modal intervention to benefit is not 
known. 
 
Table 13. Summary Box: Prevention of dementia  
Intervention  Level of evidence Recommendation 
Prevention of dementia There is no evidence at present to 
support any drug intervention to 
prevent dementia. There is type II 
evidence that antihypertensive 
therapy may be helpful, but further 
studies are required. 
B 
Treatment of vascular risk 
factors 
There is type III and IV evidence 
that vascular risk factors are 
inadequately recognized and 
managed in people with dementia, 
and that recognition and 
management should be as active as 
in those without dementia. 
D 
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Table 14. Summary Box: All recommendations 
Intervention  Level of evidence Recommendation 
Assessment and 
diagnosis  
  
Making a diagnosis of 
dementia subtype  
 
There is type I evidence that the clinical 
diagnosis of dementia subtype 
according to internationally agreed 
consensus criteria is accurate, but 
some of the newly proposed criteria 
still require validation.  
A 
 
 
 
Use of structural brain 
imaging for diagnosis  
 
 
There is type I evidence that CT or MRI 
should be used to exclude other 
cerebral pathologies and to help 
establish the subtype diagnosis.  
 
A 
 There is type II evidence that medial 
temporal atrophy can be helpful in the 
diagnosis of Alzheimer’s disease, and 
for distinguishing Alzheimer's disease 
from dementia with Lewy bodies in 
some cases. 
B 
 
Use of SPECT or PET 
imaging  
 
 
There is type I evidence that perfusion 
(HMPAO) SPECT or FDG PET can 
differentiate between Alzheimer’s 
disease, vascular dementia and 
frontotemporal dementia.  
 
A 
 There is type II evidence that FDG PET 
is superior to perfusion (HMPAO) 
B 
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SPECT in the diagnosis of dementia. 
 There is type I evidence that 
dopaminergic SPECT or PET imaging 
can help differentiate dementia with 
Lewy bodies from Alzheimer’s disease. 
 
A 
 There is type I evidence that amyloid 
PET imaging can identify patients with 
elevated amyloid burden in the brain, 
and so be a useful diagnostic marker 
for Alzheimer’s disease. 
 
A 
 There is type I evidence that MIBG can 
differentiate dementia with Lewy 
bodies from Alzheimer’s disease. 
A 
 
CSF biomarkers  
 
 
There is type II evidence that CSF 
markers of amyloid and tau may be 
useful diagnostic markers for 
Alzheimer's disease, but further 
standardization and validation is 
required before they can be used 
clinically.  
 
B 
 
Alzheimer’s disease 
  
Treatment with 
cholinesterase 
inhibitors and 
memantine  
There is type I evidence for the efficacy 
of cholinesterase inhibitors in the 
treatment of mild to moderate 
Alzheimer's disease and of severe 
dementia. 
A 
 There is type I evidence for memantine  
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in moderate to severe Alzheimer's 
disease. 
 There is type I evidence that 
cholinesterase inhibitors should not be 
stopped just because the point of 
severe dementia has been reached. 
A 
Switching between 
cholinesterase 
inhibitors 
 
There is type II evidence to support the 
switching of one cholinesterase 
inhibitor to another if the first is not 
tolerated or effective. 
B 
Combination therapy   There is type I evidence for adding 
memantine to a cholinesterase 
inhibitor.   
B 
Dementia with Lewy 
bodies 
  
Cholinesterase 
inhibitors 
There is type I evidence to support 
treatment with rivastigmine and 
donepezil in Lewy body dementia, both 
dementia with Lewy bodies and 
Parkinson’s disease dementia. 
A 
   
Memantine There is type I evidence that 
memantine produces global 
improvements in Lewy body dementia, 
both dementia with Lewy bodies and 
Parkinson’s disease dementia, but the 
pattern of cognitive and 
neuropsychiatric responsiveness 
remains uncertain.  
B 
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Vascular dementia   
Treatment with 
cholinesterase 
inhibitors and 
memantine  
 
There is type I evidence showing small 
cognitive improvements with both 
cholinesterase inhibitors and 
memantine in vascular dementia. 
However, benefits in terms of global 
outcome are not seen and adverse 
events for cholinesterase inhibitors 
(but not memantine) are significantly 
greater than placebo. Evidence 
indicates that neither cholinesterase 
inhibitors nor memantine should be 
prescribed to people with vascular 
dementia, though those with mixed 
vascular dementia and Alzheimer’s 
disease may benefit. 
A 
Frontotemporal 
dementia 
  
Cholinesterase 
inhibitors 
There is type I evidence that 
cholinesterase inhibitors are not 
recommended for the treatment of 
frontotemporal dementia. 
A 
SSRIs There is type II evidence that SSRIs may 
help some behavioural aspects of 
frontotemporal dementia, but do not 
improve cognition. Studies are mixed 
and further evidence is needed. 
B 
Memantine There is type I evidence that 
memantine is not recommended for 
frontotemporal dementia. 
A 
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Progressive 
supranuclear palsy 
Type II evidence indicates that no 
treatments can be recommended at 
the current time. 
B 
Mild cognitive 
impairment 
  
Treatment with 
cholinesterase 
inhibitors and vitamin 
E 
There is type I evidence that 
cholinesterase inhibitors are not 
effective in reducing the risk of 
developing Alzheimer’s disease and 
type I evidence that vitamin E is not 
effective in reducing the risk of 
Alzheimer’s disease. 
A 
Primary care    
initiation and 
prescription of anti-
dementia drugs 
There is type IV evidence to support 
the current practice of non-specialist 
initiation of these drugs. 
D 
 There is type II evidence indicating no 
significance differences between the 
ongoing prescription and monitoring of 
the drugs between memory clinic and 
GP-led services. 
B 
 
End of life care    
Withdrawal of anti-
dementia drugs 
There is type I evidence that continuing 
donepezil may decrease the rate of 
functional decline in moderate/severe 
dementia. There is type III evidence 
that it may be inappropriate to 
prescribe memantine and 
cholinesterase inhibitors in advanced 
C 
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dementia towards the end of life. 
Other treatments for 
dementia 
 
  
Hormone 
Replacement Therapy 
(HRT) in prevention 
and treatment of 
Alzheimer’s disease in 
post-menopausal  
women 
There is type I evidence that HRT is not 
effective either in treating cognition in 
Alzheimer’s disease, or for the primary 
prevention of all-cause dementia or 
Alzheimer’s disease. 
 
A 
 There is type I evidence that HRT is 
harmful. HRT should not be prescribed 
either as a prevention or treatment for 
dementia, including Alzheimer’s 
disease. 
A 
Folate and vitamin 
B12 for dementia 
There is type I evidence that 
supplementation with folic acid with or 
without vitamin B12 does not benefit 
cognition in people with dementia. On 
current evidence, neither vitamin B12 
nor folate, either singly or in 
combination, can be recommended as 
treatments for dementia, or for 
dementia prevention. 
A 
Statins for the 
treatment or 
prevention of 
dementia 
There is type I evidence that statins do 
not prevent dementia.  
A 
 There is type II evidence that statins do B 
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not produce cognitive benefits in 
Alzheimer’s disease. 
 
 
Souvenaid 
There is type II evidence indicating 
possible benefits of Souvenaid on 
cognition but effects are variable 
between studies and no effect on 
global outcomes has been shown. 
Souvenaid is not recommended until 
further evidence becomes available. 
B 
rTMS and tDCS There is type II evidence indicating 
benefit of rTMS and tDCS on cognition 
but effects may not be sustained. 
These treatments are not 
recommended until further evidence 
becomes available. 
B 
Disease modifying 
therapies 
  
Gamma secretase 
inhibition 
There is type I evidence that gamma 
secretase inhibitors are not effective in 
Alzheimer’s disease. 
A 
 There is type I evidence that 
tarenflurbil is not effective in 
Alzheimer’s disease. 
A 
Vaccination and 
immunization studies 
There is preliminary type II evidence of 
their effect in Alzheimer’s disease on 
some endpoints, but also type II 
evidence that amyloid lowering does 
not affect clinical course. Amyloid-
lowering agents should not be 
prescribed until the optimal disease 
stage, safety and efficacy data are 
B 
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available. 
Prevention of 
dementia 
  
Prevention of 
dementia 
There is no evidence at present to 
support any drug intervention to 
prevent dementia. There is type II 
evidence that antihypertensive therapy 
may be helpful, but further studies are 
required. 
B 
Treatment of vascular 
risk factors 
There is type III and IV evidence that 
vascular risk factors are inadequately 
recognized and managed in people 
with dementia, and that recognition 
and management should be as active 
as in those without dementia. 
D 
Strength of recommendation 
A Directly based on category I evidence 
B Directly based on category II evidence or extrapolated# recommendation from category 
I evidence 
C Directly based on category III evidence or extrapolated# recommendation from category 
I or II evidence  
D Directly based on category IV evidence or extrapolated# recommendation from 
category I, II or III evidence 
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